BOZEN, Italy, Aug. 2, 2024
/PRNewswire/ -- OncoBeta®, a leading medical device company
specialising in innovative epidermal radioisotope therapies, has
announced the expansion of Rhenium-SCT® (Skin Cancer Therapy)
treatment services in Italy with
the Bolzano Hospital the latest to come on board. This marks a
significant advancement in the availability of non-melanoma skin
cancer (NMSC) treatment options within the country.
Rhenium skin cancer therapy is an advanced radionuclide therapy
that offers a painless,*1,2
single-session,†1-3 non-invasive‡1 treatment
without disfiguring scarring.1,4 Treatment with
Rhenium-SCT employs a superficial application of a paste containing
β-emitting particles directly over the NMSC lesion, targeting
cancer cells without the need for surgery.1,4
Dr. Mohsen Farsad at Bolzano
Hospital has been impressed with the Rhenium-SCT device, noting,
"I have witnessed impressive outcomes with several patients
treated here in Italy already, and
am pleased with the design of the device technology."
"Rhenium skin cancer therapy fulfills many patients' desires
for a non-surgical alternative for the treatment of NMSCs
especially in relation to difficult localisations. I am pleased to
continue treating suitable patients with Rhenium-SCT," adds Dr.
Farsad.
Shannon D. Brown III, CCO at
OncoBeta, says, "While surgical intervention remains the
standard-of-care for NMSC treatment, it often leads to suboptimal
outcomes. Rhenium-SCT offers a non-surgical alternative with a
simple application directly to the area needed to treat, and allows
patients to resume their daily activities with minimal
disruption."
According to GLOBOCAN estimates, the number of new NMSC cases in
Italy is projected to rise from
29,000 to 41,700 between 2022 and 2045.5 Epidemiological
data for Europe shows an annual
incidence rate of NMSCs at 129.3 cases per 100,000 men and 90.8 per
100,000 women. Basal cell carcinoma (BCC) accounts for
approximately 15% of all diagnosed cancers in Italy, with an annual incidence of around 100
cases per 100,000 inhabitants.6
Dr. Gerhard Dahlhoff, Medical
Director at OncoBeta, emphasised, "Rhenium-SCT enables targeted,
non-invasive treatment of NMSCs while preserving adjacent healthy
tissue. This patient-friendly approach underscores our commitment
to enhancing treatment options for those affected by
NMSCs."
Rhenium-SCT is currently available in Germany, Austria, Switzerland, Italy, Spain,
United Kingdom, South Africa and Australia. Rhenium-SCT will be provided to
patients at Bolzano Hospital by OncoBeta's distribution partner,
DSD Pharma.
About the Rhenium-SCT® (Skin Cancer
Therapy)
Non-melanoma skin cancer (NMSC) is the most common
form of cancer in humans.1 The most common cause of NMSC
is sun exposure, while other predisposing factors include genetic
skin conditions and immunosuppressive diseases or
treatments.1,4
The Rhenium-SCT is a painless,*1,2 single
session,†1-3 non-invasive‡1 therapy that
provides aesthetic results, even in cases otherwise considered
difficult to treat.1,4,7 The Rhenium-SCT utilizes the
radioisotope rhenium-188 in an epidermal application with optimal
properties for the treatment of NMSCs (non-melanoma skin cancers).
The Rhenium-SCT is a precise, personalized therapy that is only
applied to the area needed to treat without affecting the healthy
tissue.4,7 The specially designed device ensures the
Rhenium-SCT compound never comes in direct contact with the
patient's skin and the application is safe and simple for the
applying physician. Most cases of NMSCs (basal cell carcinomas and
squamous cell carcinomas) can be treated using the Rhenium-SCT in
one single session. †1-4 Scar-free healing of the
treated lesion area and the regeneration of healthy tissue occurs
usually within a few weeks after treatment.1,7,8
About OncoBeta®
OncoBeta® with its headquarters
located in Garching near Munich,
Germany, is a privately held medical device company,
specializing in the development and commercialization of
state-of-the-art, innovative therapies. Since its foundation,
OncoBeta has concentrated its efforts on the development,
regulatory approval(s) and commercialization of the epidermal
radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting
NMSCs. OncoBeta has perfected the customized application and device
management system in conformity with all health, safety, and
environmental protection regulatory standards.
Find out more about the Rhenium-SCT at www.oncobeta.com
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/oncobeta/
Instagram: https://www.instagram.com/oncobeta_gmbh/
About DSD Pharma
DSD Pharma is a distributor for
diagnostics, theranostics and radiopharmaceutical/medical devices
in the field of nuclear medicine and radiopharmaceuticals. DSD
Pharma offers a product portfolio developed together at the
forefront of research to its customers. This ensures the safety of
latest technologies for the HCP and the best available
diagnosis/theranosis/therapy for the patient.
Find out more about DSD Pharma at www.dsd-pharma.com
Forward-looking statements
This announcement includes
forward-looking statements that involve risks, uncertainties and
other factors, many of which are outside of OncoBeta's control and
which could cause actual results to differ materially from the
results discussed in the forward-looking statements.
Forward-looking statements include statements concerning OncoBeta's
plans, objectives, goals, future events, performance and/or other
information that is not historical information. All such
forward-looking statements are expressly qualified by these
cautionary statements and any other cautionary statements which may
accompany the forward-looking statements. OncoBeta undertakes no
obligation to publicly update or revise forward-looking statements
to reflect subsequent events or circumstances after the date made,
except as required by law.
*No reported pain during procedure.1,2
†Complete tumour regression in 98.5% of lesions
treated.3
‡A treatment is considered non-invasive when no cut or break in
the skin is created.9
References
- Castellucci P, et al. Eur J Nucl Med Mol Imaging. 2021;
48: 1511–1521.
- Cipriani C, et al. J Dermatol Treat. 2022;33(2):969–975.
Epub 22 Jul 2020.
- Cipriani C, et al. In Therapeutic Nuclear Medicine.
2014. RP Baum (Ed), New York:
Springer.
- Tietze JK, et al. Clin Nucl Med. 2023;48:869–76.
- Global Burden of Disease Cancer Collaboration, et al. JAMA
Oncol. 2019;5(12):1749-1768.
- Sordi E, et al. Epidemiologia. 2024;5:1–10.
- Cipriani C, et al. International J Nucl Med. 2017;
July:114–112.
- Sedda AF, et al. Clin Exp Dermatol.
2008;33(6):745–749.
- Australian Therapeutic Goods Administration. Acronym and
glossary of terms. Available at:
https://www.tga.gov.au/resources/acronyms-and-glossary-terms.
(Accessed June 2024).
Contact:
Jane Morey
***@moreymedia.com.au
Photos:
https://www.prlog.org/13032012
Press release distributed by PRLog
View original
content:https://www.prnewswire.com/news-releases/oncobeta-announces-the-expansion-of-rhenium-sct-for-non-melanoma-skin-cancer-patients-in-italy-302213212.html
SOURCE OncoBeta GmbH